Hepatology has evolved from a focus on curing Hepatitis C to the next major threat within hepatology – Nonalcoholic Fatty Liver Disease (NAFLD). Current hepatology dynamics the REACH team is tracking include:
- The rising global prevalence of NAFLD
- Potential for a long-awaited FDA approval for Nonalcoholic Steatohepatitis (NASH) with Madrigal Pharmaceuticals’ resmetirom
- Autoimmune liver diseases with high unmet therapeutic need (e.g., Primary Biliary Cholangitis, Primary Sclerosing Cholangitis
Search Hepatology diseases we cover